Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1721484 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.68Day +13.50%Mkt cap $10M1Y −57.3%Off 52W high −61.4%Vol (1Y) 116.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,297 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.7% of sh out |
| Days to cover4.8d |
| 13F net flow (QoQ)+1.76% |
| Top-10 13F concentration92.4% |
| Next report (est.)2026-08-11 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$1.2M |
| Earnings (TTM)-$22.4M |
| ROE−164.7% |
| Net margin−1893.6% |
| Sales growth 3Y−0.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+33.5% |
| 1Y−57.3% |
| 3Y−98.0% |
| 5Y−98.8% |
| Since incept. (ann.)−57.7% |
Total return through 2026-07-30 · series begins 2021-02-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)116.0% |
| Ann. volatility (3Y)141.3% |
| Sharpe (1Y)−0.18 |
| Sharpe (3Y)−0.33 |
| Max drawdown (1Y)−71.7% |
| Max drawdown (3Y)−98.6% |
| Beta (3Y vs SPY)−1.24 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 542,032 | $563,713 | 3.08% | new |
| MILLENNIUM MANAGEMENT LLC | 446,725 | $464,594 | 2.54% | new |
| BlackRock, Inc. | 224,198 | $233,166 | 1.28% | +2138.4% |
| GEODE CAPITAL MANAGEMENT, LLC | 203,618 | $211,764 | 1.16% | +43.9% |
| ADAR1 Capital Management, LLC | 200,000 | $208,000 | 1.14% | new |
| JANE STREET GROUP, LLC | 185,656 | $193,082 | 1.06% | new |
| HRT FINANCIAL LP | 118,891 | $123,000 | 0.68% | +891.7% |
| Beacon Pointe Advisors, LLC | 100,000 | $104,000 | 0.57% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.19 | — | $398,000 | +4.5% |
| 2025-12-31 | 2026-03-17 | — | — | $365,000 | −39.5% |
| 2025-09-30 | 2025-11-04 | −$0.39 | — | $137,000 | −82.3% |
| 2025-06-30 | 2025-08-13 | −$0.33 | — | $316,000 | −32.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-11 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
Reportable Segment Aggregation Before Other Operating 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
